Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate

Brain and Development

Volumn 28, Issue 9, 2006, Pages 549-553

  Ugras, Meltem ^a   Yakinci, Cengiz ^a  

^a INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Hepatotoxicity; Protein C; Protein S; Valproate

Indexed keywords

PROTEIN C; PROTEIN S; VALPROIC ACID;

ADOLESCENT; ANAMNESIS; ANTICOAGULATION; ARTICLE; BLOOD CELL COUNT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; EPILEPSY; EVALUATION; FEMALE; HUMAN; LIVER TOXICITY; MALE; THROMBOCYTE COUNT;

ADOLESCENT; ANTICOAGULANTS; ANTICONVULSANTS; BLOOD CELL COUNT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENZYME ACTIVATION; EPILEPSY; FEMALE; FIBRINOGEN; HUMANS; INFANT; MALE; PROTEIN C; PROTEIN S; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; VALPROIC ACID;

EID: 33747894585     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2006.03.009     Document Type: Article

References (35)

1. Chang B.S., and Lowenstein D.H. Mechanism of disease Epilepsy. N Engl J Med 349 (2003) 1257-1266
2. Holmes G.L., and Stafstrom C.E. The epilepsies. In: David R.B. (Ed). Child and Adolescent Neurology (1998), St. Louis, Mosby 183-234
3. Delgado M.R., Riela A.R., Mills J., Browne R., and Roach E.S. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 9 (1994) 311-314
4. May R.B., and Sunder T.R. Hematologic manifestations of long term valproate therapy. Epilepsia 34 (1993) 1098-1101
5. Gidal B., Spencer N., Maly M., Pitterle M., Williams E., Collins M., et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 44 (1994) 1418-1422
6. Neophytides A.N., Nutt J.G., and Lodish J.R. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol 5 (1979) 389-390
7. Gesundheit B., Kirby M., Lau W., Koren G., and Abdelhaleem M. Thrombocytopenia and megakaryocyte dysplasia: an adverse effect of valproic acid treatment. J Pediatr Hematol Oncol 24 (2002) 589-590
8. Voss H.V., Schulte-Berbuhl R., and Gobel U. Side effects of sodium valproate(sodium di-n-propylacetate) on malonylaldehyde-production and other platelet function tests. Minerva Pediatr 30 (1978) 1397-1404
9. Barr R.D., Copeland S.A., Stockwell M.L., Morris N., and Kelton R.C. Valproic acid and immune thrombocytopenia. Arch Dis Child 57 (1982) 681-684
10. Sandler R.M., Emberson C., Roberts G.E., Voak D., Darnborough J., and Heeley A.F. IgM platelet autoantibody due to sodium valproate. Br Med J 2 (1978) 1683-1684
11. Ganick D.J., Sunder T., and Finley J.L. Severe hematologic toxicity of valproic acid. A report of four patients. Am J Pediatr Hematol Oncol 12 (1990) 80-85
12. Sunder T., and May R.B. Valproate-induced macrocytosis. Epilepsia 29 (1988) 670
13. Verrotti A., Greco R., Matera V., Altobelli E., Morgese G., and Chiarelli F. Platelet count and function in children receiving sodium valproate. Pediatr Neurol 21 (1999) 611-614
14. Voss H.V., Petrich C., Karch D., Schulz H.U., and Göbel U. Sodium valproate and platelet function. Br Med J 2 (1976) 179
15. Voss H.V., Petrich C., Karch D., Schulz H.U., and Göbel U. Hemorrhagic diathesis and platelet dysfunction in children under treatment with sodium valproate. Epilepsia 19 (1978) 113-114
16. Brandl U., Wenzel D., and Ott R. Valproate-induced von Willebrand-Jürgens-syndrome. Epilepsia 27 (1986) 588
17. Dale B.M., Purdie G.H., and Rischbieth R.H. Fibrinogen depletion with sodium valproate. Lancet 1 (1978) 1316-1317
18. Kreut W., Linde R., Funk M., Meyer-Schrod R., Föll E., and Nowak-Göttl U. Valproate therapy induces von Willebrand disease type 1. Epilepsia 33 (1992) 178-184
19. Ojemann L.M., Wilensky A.J., Temkin N.R., and Lovely M.P. Fibrinogen and valproic acid. Epilepsia 22 (1981) 242-243
20. Gruppo R., DeGrauw A., Fogelson H., and Glauser T. Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. J Pediatr 137 (2000) 714-718
21. Banerjea M.C., Diener W., Kutschke G., Schnelbe H.J., Korinthenberg R., and Sutor A.H. Pro- and anticoagulatory factors under sodium valproate-therapy in children. Neuropediatrics 33 (2002) 215-220
22. Lanskowski P. Hemostasis. In: Lanzkowski P. (Ed). Manual of Pediatric Hematology and Oncology (1995), Churchill Livingstone, San Diego 239-271
23. Fischbach F.T. Blood studies. In: Fischbach F.T. (Ed). A manual of laboratory and diagnostic tests (1996), Lippincott, Philadelphia 23-146
24. Serdaroglu G., Tutuncuoglu S., Kavakli K., and Tekgul H. Coagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid. J Child Neurol 17 (2002) 41-43
25. Anderson G.D., Lin Y.X., Berge C., and Ojemann G.A. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 87 (1997) 252-256
26. Tong V., Teng X.W., Chang K.H., and Abbott F.S. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci (2005)
27. Eve A.R. Drug-induced hepatotoxicity. In: Walker W.A., Goulet O., Kleinmann R.E., and Sherman P.M. (Eds). Pediatric Gastrointestinal Disease (2004), BC Decker, Ontario 1219-1240
28. De Wolf C.J., Cupers R.M., Bertina R.M., and Vos H.L. Initiation of Protein S mRNA synthesis in human liver and various cell lines. J Thromb Haemost 3 2 (2005) 410-412
29. De Stefano V., Finazzi G., and Mannucci P.M. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 87 (1996) 3531-3544
30. Seligsohn U., and Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 344 (2001) 1222-1231
31. Hauser E., Seidl R., Freilinger M., Male C., and Herkner K. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 18 (1996) 105-109
32. Demircioǧlu S., Soylu A., and Dirik E. Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children. Pediatr Neurol 23 (2000) 142-146
33. Murphy J., Groover R., and Hodge C. Hepatotoxic effects in a child receiving valproate and carnitine. J Pediatr 123 (1993) 318-320
34. Nizzi Jr. F.A., and Kaplan H.S. Protein C and S deficiency. Semin Thromb Hemost 25 3 (1999) 265-272
35. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 353 (1999) 1167-1173